IBA and Shreeji sign multi‑site agreement for four cyclotrons to expand PET radiopharmaceutical manufacturing across India Louvain-la-Neuve, Belgium – 19 February 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology with a preeminent position in nuclear medicine, and Shreeji (Shreeji Imaging and Diagnostic Centre Pvt. Ltd.), a leading Indian manufacturer and distributor of fluorodeoxyglucose (FDG) and positron emission tomography (PET) radiopharmaceuticals, have signed a multi-site agreement for the delivery and installation of four mid-en...
IBA et Shreeji signent un accord pour quatre cyclotrons afin d’étendre la production de radiopharmaceutiques TEP en Inde Louvain-la-Neuve, Belgium – 19 février 2026 – IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d'accélérateurs de particules et acteur de premier plan en médecine nucléaire, et Shreeji (Shreeji Imaging and Diagnostic Centre Pvt. Ltd.), l'un des principaux fabricants et distributeurs indiens de fluorodéoxyglucose (FDG) et de radiopharmaceutiques pour la tomographie par émission de positons (TEP), ont signé un contrat pour la livraison et l'i...
IBA – ACQUISITION OF OWN SHARES Louvain-la-Neuve, Belgium, February 16th, 2026 – 6 PM CET – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on February 2nd, 2026. Under this program, IBA has requested a financial intermediary to repurchase up to 400,000 IBA ordinary shares on its behalf under the terms of a mandate with validity until September 30th, 2026 (included), effective as from February 3rd, 2...
IBA – ACQUISITION D’ACTIONS PROPRES Louvain-la-Neuve, Belgique, 16 février 2026 – 18h00 – Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") communique par la présente certaines informations relatives à son programme de rachat d'actions annoncé le 2 février 2026. Dans le cadre de ce programme, IBA a demandé à un intermédiaire financier de racheter en son nom un maximum de 400.000 actions ordinaires IBA selon les termes d'un mandat valable jusqu'au 30 septembre 2026 et effectif ...
Home Invest reports results in line with our expectations at €1,21 EPRA EPS. It guides €1,23 EPRA EPS in FY26, slightly ahead of our expectation of € 1,20. At 1H25 results, Home Invest confirmed our thesis that the building right in Louvain-La-Neuve will not get renewed. As of the announcement Home Invest started to underperform (-7,1%) the EPRA index (+8,6%). The UCL has time until June 2026 to respond. This headwind will keep EPRA EPS growth muted, despite the stellar operational results: 98,...
CMB.TECH ANNOUNCES Q4 2025 RESULTS ON 26/02/2026 Antwerp, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT & Euronext: CMBT) (“CMBT”, “CMB.TECH” or “the Company”) will release its fourth quarter 2025 earnings prior to market opening on Thursday 26 February 2026 and will host a conference call at 8 a.m. EST / 2 p.m. CET to discuss the results for the quarter. The call will be a webcast with an accompanying slideshow. You can find the details of this conference call below and on the of the website. The presentation, recording & transcript will also be available on this page....
IBA – ACQUISITION OF OWN SHARES Louvain-la-Neuve, Belgium, February 10th, 2026 – 6 PM CET – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on February 2nd, 2026. Under this program, IBA has requested a financial intermediary to repurchase up to 400,000 IBA ordinary shares on its behalf under the terms of a mandate with validity until September 30th, 2026 (included), effective as from February 3rd, 202...
IBA – ACQUISITION D’ACTIONS PROPRES Louvain-la-Neuve, Belgique, 10 février 2026 – 18h00 – Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") communique par la présente certaines informations relatives à son programme de rachat d'actions annoncé le 2 février 2026. Dans le cadre de ce programme, IBA a demandé à un intermédiaire financier de racheter en son nom un maximum de 400.000 actions ordinaires IBA selon les termes d'un mandat valable jusqu'au 30 septembre 2026 et effectif à pa...
CMB.TECH FLEET UPDATE Antwerp, Feb. 09, 2026 (GLOBE NEWSWIRE) -- CMB.TECH NV (“CMBT”, “CMB.TECH” or “the Company”) (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) has sold two vessels, generating a capital gain of approximately 98.2 million USD in total. Euronav CMB.TECH has sold two VLCCs: Ingrid (2012, 314,000 dwt) and Ilma (2012, 314,000 dwt). The sale will generate a capital gain of approximately 98.2 million USD in Q2 2026, based on the net sales price and book values. The vessels will be delivered to their new owner in Q2 2026. Announcement Q4 2025 result...
A director at Atenor SA bought 251,231 shares at 2.800EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
After today's changes (ASMi out, UCB in), we maintain a balanced approach in our Dynamic Top Pick List, with a particular emphasis on value stocks that have been overlooked. Our defensive holdings are overweight, including real estate, which stands to benefit from lower interest rates. We remove ASMi from our Dynamic Top Pick List as the recent share price performance has driven the valuation meaningfully ahead of fundamentals. Since early December, FY27 diluted EPS expectations have risen by a...
Onward announces enrolment of the first participant in the Empower BP trial. The trial evaluates the ARC-IM system to address blood pressure instability in SCI patients. We note that Onward plans an interim analysis of the efficacy results in 2H26, which could accelerate timelines if fewer total patients are required. Short-term, we look forward to the FY25 results to gain a view on the ARC-EX commercial launch (9M25: 70 devices sold). We reiterate our € 8.9 TP and BUY rating.
Yesterday, the German government (via KfW) secured a 25.1% "blocking minority" in TenneT's German operations. The €3.3bn deal ends years of negotiations between Germany and the Netherlands. The deal is struck at the same equity value following the capital contribution (46%) from ABP, GIC and Norges Bank in 09/25 at a total equity value of 13.3bn. TenneT NL will hold the remaining 28.9%. We understand from the Handelsblatt that KfW will invest an additional €1.7bn before 2035. TenneT GE will no...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.